235 related articles for article (PubMed ID: 19222901)
1. In-vitro respiratory drug absorption models possess nominal functional P-glycoprotein activity.
Madlova M; Bosquillon C; Asker D; Dolezal P; Forbes B
J Pharm Pharmacol; 2009 Mar; 61(3):293-301. PubMed ID: 19222901
[TBL] [Abstract][Full Text] [Related]
2. Digoxin net secretory transport in bronchial epithelial cell layers is not exclusively mediated by P-glycoprotein/MDR1.
Hutter V; Chau DY; Hilgendorf C; Brown A; Cooper A; Zann V; Pritchard DI; Bosquillon C
Eur J Pharm Biopharm; 2014 Jan; 86(1):74-82. PubMed ID: 23816640
[TBL] [Abstract][Full Text] [Related]
3. Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood-brain barrier in rats.
Sugimoto H; Hirabayashi H; Kimura Y; Furuta A; Amano N; Moriwaki T
Drug Metab Dispos; 2011 Jan; 39(1):8-14. PubMed ID: 20962062
[TBL] [Abstract][Full Text] [Related]
4. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
Taub ME; Podila L; Ely D; Almeida I
Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo evaluation of the effects of piperine on P-gp function and expression.
Han Y; Chin Tan TM; Lim LY
Toxicol Appl Pharmacol; 2008 Aug; 230(3):283-9. PubMed ID: 18417181
[TBL] [Abstract][Full Text] [Related]
6. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia.
Stephens RH; O'Neill CA; Warhurst A; Carlson GL; Rowland M; Warhurst G
J Pharmacol Exp Ther; 2001 Feb; 296(2):584-91. PubMed ID: 11160647
[TBL] [Abstract][Full Text] [Related]
7. The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672.
Elsby R; Gillen M; Butters C; Imisson G; Sharma P; Smith V; Surry DD
Drug Metab Dispos; 2011 Feb; 39(2):275-82. PubMed ID: 21075975
[TBL] [Abstract][Full Text] [Related]
8. P-glycoprotein (MDR1) functional activity in human alveolar epithelial cell monolayers.
Endter S; Becker U; Daum N; Huwer H; Lehr CM; Gumbleton M; Ehrhardt C
Cell Tissue Res; 2007 Apr; 328(1):77-84. PubMed ID: 17165089
[TBL] [Abstract][Full Text] [Related]
9. Echinacea purpurea and P-glycoprotein drug transport in Caco-2 cells.
Hansen TS; Nilsen OG
Phytother Res; 2009 Jan; 23(1):86-91. PubMed ID: 18688789
[TBL] [Abstract][Full Text] [Related]
10. The complexity of intestinal absorption and exsorption of digoxin in rats.
Yao HM; Chiou WL
Int J Pharm; 2006 Sep; 322(1-2):79-86. PubMed ID: 16781832
[TBL] [Abstract][Full Text] [Related]
11. Lack of difference in pulmonary absorption of digoxin, a P-glycoprotein substrate, in mdr1a-deficient and mdr1a-competent mice.
Manford F; Riffo-Vasquez Y; Spina D; Page CP; Hutt AJ; Moore V; Johansson F; Forbes B
J Pharm Pharmacol; 2008 Oct; 60(10):1305-10. PubMed ID: 18812023
[TBL] [Abstract][Full Text] [Related]
12. A simplified protocol employing elacridar in rodents: a screening model in drug discovery to assess P-gp mediated efflux at the blood brain barrier.
Kallem R; Kulkarni CP; Patel D; Thakur M; Sinz M; Singh SP; Mahammad SS; Mandlekar S
Drug Metab Lett; 2012 Jun; 6(2):134-44. PubMed ID: 23061481
[TBL] [Abstract][Full Text] [Related]
13. 20(S)-ginsenoside Rh2 noncompetitively inhibits P-glycoprotein in vitro and in vivo: a case for herb-drug interactions.
Zhang J; Zhou F; Wu X; Gu Y; Ai H; Zheng Y; Li Y; Zhang X; Hao G; Sun J; Peng Y; Wang G
Drug Metab Dispos; 2010 Dec; 38(12):2179-87. PubMed ID: 20837659
[TBL] [Abstract][Full Text] [Related]
14. Caco-2 cell methodology and inhibition of the P-glycoprotein transport of digoxin by Aloe vera juice.
Djuv A; Nilsen OG
Phytother Res; 2008 Dec; 22(12):1623-8. PubMed ID: 19003953
[TBL] [Abstract][Full Text] [Related]
15. Time- and passage-dependent characteristics of a Calu-3 respiratory epithelial cell model.
Haghi M; Young PM; Traini D; Jaiswal R; Gong J; Bebawy M
Drug Dev Ind Pharm; 2010 Oct; 36(10):1207-14. PubMed ID: 20374185
[TBL] [Abstract][Full Text] [Related]
16. A combined cell based approach to identify P-glycoprotein substrates and inhibitors in a single assay.
Balimane PV; Chong S
Int J Pharm; 2005 Sep; 301(1-2):80-8. PubMed ID: 16023314
[TBL] [Abstract][Full Text] [Related]
17. Induction of rat intestinal P-glycoprotein by spironolactone and its effect on absorption of orally administered digoxin.
Ghanem CI; Gómez PC; Arana MC; Perassolo M; Delli Carpini G; Luquita MG; Veggi LM; Catania VA; Bengochea LA; Mottino AD
J Pharmacol Exp Ther; 2006 Sep; 318(3):1146-52. PubMed ID: 16740618
[TBL] [Abstract][Full Text] [Related]
18. P-glycoprotein is not involved in the differential oral potency of naloxone and naltrexone.
Kanaan M; Daali Y; Dayer P; Desmeules J
Fundam Clin Pharmacol; 2009 Oct; 23(5):543-8. PubMed ID: 19656202
[TBL] [Abstract][Full Text] [Related]
19. P-Glycoprotein expression in human retinal pigment epithelium cell lines.
Constable PA; Lawrenson JG; Dolman DE; Arden GB; Abbott NJ
Exp Eye Res; 2006 Jul; 83(1):24-30. PubMed ID: 16530756
[TBL] [Abstract][Full Text] [Related]
20. Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana.
Zhu HJ; Wang JS; Markowitz JS; Donovan JL; Gibson BB; Gefroh HA; Devane CL
J Pharmacol Exp Ther; 2006 May; 317(2):850-7. PubMed ID: 16439618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
